pharmaphorum

MARCH 24, 2022

The examples remain few and far between, however, as in recent decades the pharma industry has turned its attention to synthetic molecules and biologics like antibodies. The platform uses an artificial intelligence (AI) algorithm to zero in on the genes encoding natural products based on their computationally predicted human target.

Medicine 105

Medicine Genomics Genome Engineer 105

The Pharma Data

SEPTEMBER 11, 2021

Boehringer Ingelheim believes Twist’s ability to generate potent, diverse therapeutic antibodies by mining its comprehensive libraries, combined with our extensive capabilities and experience in drug discovery and development, will enable us to deliver breakthrough opportunities to patients,” said Clive R. About Twist Bioscience Corporation.

Antibody 52

Antibody DNA Containment Manufacturing 52

pharmaphorum

DECEMBER 5, 2022

The French biotech says VLA1553 met its objective in the phase 3 study, with 99% of patients exhibiting an antibody response against the virus 12 months after receiving a single dose of the shot, with no evidence of a tailing off in levels in the last six months. It will continue for up to five years.

Vaccination 98

Vaccination Vaccine Antibody Allergies 98

Pharmaceutical Technology

JULY 5, 2022

On leaving the liver cells, the virus hijacks bits of cell membrane and conceals itself from antibodies that would have isolated the virus before it travelled far through the bloodstream. HAV usually hijacks TENT4 and utilises it for the replication of its own genome.

Protein 130

Protein RNA Genome Genomics 130

pharmaphorum

OCTOBER 4, 2022

AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 million. The LogicBio deal is the latest in a string of acquisitions for AstraZeneca.

Gene Editing 64

Gene Editing Gene Genome Genomics 64

XTalks

JANUARY 21, 2025

The liquid portion of the blood (serum or plasma) containing antibodies is separated and tested using the Liason Biotrin parvovirus B19 IgG plus test on a Liason XL analyzer. If parvovirus B19 antibodies are present, they bind to the chemicals and particular particles in the test, producing a light signal.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

The Pharma Data

OCTOBER 9, 2021

Roche (SIX RO, ROG; OTCQX RHHBY) now posted that gantenerumab, ananti-amyloid beta antibody developed for subcutaneous administration, has been granted Improvement Rectifier Designation by theU.S. Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s fever ( Notice). Source link: [link].

Antibody 52

Antibody In-Vitro Trials Development 52

pharmaphorum

MARCH 28, 2022

Israel-based AION Labs and German independent research institute BioMed X announced its third global call for applications to form a new start-up company focused on using AI to design and optimise antibodies for targeted therapies. . From there, they evaluate what kind of antibodies are produced. ” The Application .

Pharma Companies 98

Pharma Companies Antibody Protein Development 98

Pharmaceutical Technology

AUGUST 16, 2022

In 2019, Daiichi Sankyo entered a global development and commercialisation agreement with AstraZeneca for Daiichi Sankyo’s lead antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), in a deal worth $6.9bn. An ORR of 37% was reported for the overall trial population, with this increased to 62% in previously untreated patients.

Sales 147

Sales Trials FDA Approval Development 147

pharmaphorum

OCTOBER 5, 2022

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule.

RNA 105

RNA Genetics Dermatology Antibody 105

The Pharma Data

OCTOBER 14, 2021

Roche announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the U.S. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

Antibody 52

Antibody Medicine In-Vitro Trials 52

pharmaphorum

JANUARY 24, 2023

The cost of testing per human genome in 2006 was approximately $14 million , and in less than two decades, an average consumer-purchased genetic test costs $100. The same is becoming true for the healthcare industry, and one of the first major breakthroughs in the area was the 100,000 Genomes Project.

Genetics 98

Genetics Drugs Genome Project Biobanking 98

pharmaphorum

OCTOBER 20, 2021

It will attempt to validate the software by comparing its findings with clinical data such as brain imaging and genomics analyses to see if it can accurately detect neurocognitive impairments that can’t be found using current tests.

Trials 78

Trials Genome Genomics Bioinformatics 78

pharmaphorum

JULY 14, 2022

The antibody-drug conjugate (ADC) was turned down by NICE in draft guidance published earlier this year, leading to concerns of a disparity in access to the drug as the Scottish Medicines Consortium (SMC) had already cleared its use. NICE estimates that around 2,800 people are eligible for treatment with Piqray plus fulvestrant.

Drugs 104

Drugs Hormones Genome Genomics 104

The Pharma Data

JANUARY 24, 2021

Dr. Bond has extensive experience in the discovery and development of adoptive cell therapies, monoclonal antibodies, and cellular engineering and genome editing. As part of his work with Juno and Kite, Dr. Bond led R&D collaborations with genome editing companies including Editas Medicine and Sangamo Therapeutics.

Engineer 52

Engineer Gene Editing Genome Genomics 52

pharmaphorum

JULY 13, 2022

The first subject has now been given a dose of VERVE-101, in what is thought to be the first test in humans of an experimental CRISPR/Cas9 genome editing technique known as base editing. Through base editing, drugs replace single nucleotide in the DNA strand with another, without making double-strand breaks (DSBs) in the gene.

Gene Editing 98

Gene Editing Trials Drugs In-Vivo 98

pharmaphorum

DECEMBER 22, 2020

These followed two deals late last week – on Thursday GSK made an $85 million licensing agreement with Surface Oncology for an early-stage antibody asset, which adds a natural killer cell approach to the company’s oncology portfolio. The antibody targets PVRIG, an inhibitory protein expressed on natural killer cells (NK cells) and T-cells.

Licensing 52

Licensing Licensing Genetics Sales 52

pharmaphorum

NOVEMBER 12, 2020

In 2018, it bought Element Genomics – a spin-out of Duke University in the US – to add genome-editing technologies, and has also been growing its internal exercise at its Boston R&D hub, although so far it hasn’t advanced and gene therapies into clinical development.

Gene Therapy 52

Gene Therapy Gene Manufacturing Contract Manufacturing 52

Delveinsight

AUGUST 27, 2020

As observed in 45 younger adults, the middle dose of the vaccine triggered the production of neutralizing antibodies against SARS-CoV-2, the virus, which causes COVID-19 , in 10 patients aged 56 to 70 and 10 patients over 71. Freenome secures USD 270 Million to boost its colorectal cancer blood test.

Vaccination 53

Vaccination Vaccine Research Trials 53

The Pharma Data

MARCH 20, 2021

The vast majority of current laboratory testing for COVID-19 is based either on detection of viral antigens, nucleic acids or on detection of virus-specific antibodies in the sera of patients. Detection of virus-specific antibodies allows for diagnosis of recent symptomatic or even asymptomatic infections. SARS-CoV-2 proteome.

Protein 52

Protein Antibody Development RNA 52

Pharmaceutical Technology

FEBRUARY 3, 2023

The field of genomic medicine has reached a true turning point. Moving the viral vector field closer to the monoclonal antibody field is really what we see as the way forward.” More efficient, suspension-based cell culture processes are urgently needed in the now fast-developing genomic medicine space.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Pharmaceutical Technology

JUNE 5, 2023

Summit Therapeutics has announced data for its novel investigational bispecific antibody, ivonescimab, known as SMT112 or AK112 in a non-small cell lung cancer study. Among the subset of 63 patients with squamous histology, the progression-free survival was 11 months and 12.3 months for the overall cohort.

Genome 130

Genome Genomics Clinical Trials Clinical Trials 130

The Pharma Data

OCTOBER 14, 2021

In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Source link: [link].

Medicine 52

Medicine In-Vitro Antibody Genome 52

Roots Analysis

MARCH 24, 2022

Scientific fields involved in high throughput measurement of biological molecules are referred with the suffix- omics including, transcriptomics, genomics, proteomics and metabolomics. Genomics is the study of genetic material within a cell, and transcriptomics is the study of gene activity in different cells. Web: [link].

Clinical Research 52

Clinical Research Development Research Drug Delivery Systems 52

pharmaphorum

JULY 27, 2021

He began his career working on the human genome before moving on to screening cell lines for novel antibodies in cancer helping to develop one of the market leading drugs for the disease. The post COVID-19: We don’t need another hero appeared first on.

Compliance 66

Compliance Manufacturing Genome Genomics 66

The Pharma Data

NOVEMBER 5, 2020

Deep Genomics – Toronto-based Deep Genomics appointed Amanda Kay to the newly-created role of chief business officer. Prior to joining Deep Genomics, Kay was senior vice president of Corporate Development and a member of the executive team at Synlogic, Inc. Additionally, the company also appointed Thomas E.

Genome 40

Genome Genomics Medicine Life Science 40

The Pharma Data

NOVEMBER 3, 2020

LogicBio’s proprietary genome editing technology platform, GeneRide, enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination.

Clinical Trials 40

Clinical Trials Clinical Trials Gene Editing Genome 40

The Pharma Data

JUNE 7, 2023

Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN). Results will be presented on June 6 during an oral presentation (#9004) at the American Society of Clinical Oncology Annual Meeting (#ASCO23).

Trials 40

Trials Antibody Development Genome 40

The Pharma Data

OCTOBER 14, 2020

Potential Development of Human Monoclonal Antibody Therapeutics to SARS-CoV-2. The research is part of an ongoing collaboration between Columbia University and Tonix that focuses on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19. CHATHAM, N.J., Ilya Trakht, Ph.D.,

Vaccination 40

Vaccination Vaccine Development Medicine 40

XTalks

SEPTEMBER 30, 2020

The research shows that the activity of the immune messenger type 1 interferon (IFN) protein is diminished, either by genetic mutations or an autoimmune attack by neutralizing antibodies against it, in a subset of COVID-19 patients. These rogue antibodies blocked interferon action and were not present in patients with mild COVID-19 cases.

Antibody 135

Antibody Genetics Research In-Vitro 135

The Pharma Data

MARCH 30, 2021

KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells. About KEYTRUDA ® (pembrolizumab) Injection, 100 mg. Merck has the industry’s largest immuno-oncology clinical research program.

FDA Approval 52

FDA Approval Containment Trials Genome 52

The Pharma Data

DECEMBER 12, 2020

AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics. Alexion ‘s franchise includes Soliris (eculizumab), a first-in-class anti-complement component 5 (C5) monoclonal antibody.

Development 75

Development Regulation Medicine Containment 75

The Pharma Data

DECEMBER 10, 2020

The goal of targeting both S and N was to both activate virus-specific T cells and generate anti-SARS-CoV-2-neutralizing antibodies. ImmunityBio’s hAd5 vaccine generated robust neutralizing antibody activity that was present 14 days post-final vaccination. This press release features multimedia. Graphic: Business Wire).

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

FDA Law Blog

NOVEMBER 2, 2023

Regarding screening for risk of liver injury: “Total and/or neutralizing antibody titers are screened in many clinical studies, but how such testing is performed, the cut-offs, and the acceptance criteria are all variables that may need standardization.”

Medicine 59

Medicine Gene Therapy Gene Production 59

The Pharma Data

JULY 6, 2021

They compared these sequences with the original SARS-CoV-2 genome, cross-checking the genetic changes against their highly networked epitopes. The team obtained sequences from the newly circulating B.1.1.7 1.351 Beta, P1 Gamma, and B.1.617.2 Delta SARS-CoV-2 variants of concern.

Vaccination 52

Vaccination Vaccine Research Immune Response 52

pharmaphorum

OCTOBER 12, 2022

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.

Genome 105

Genome Genomics Medicine Development 105

The Pharma Data

MARCH 11, 2021

ALIMTA is indicated in combination with pembrolizumab and platinum chemotherapy for the initial treatment of patients with metastatic nonsquamous non-small cell lung cancer, with no EGFR or ALK genomic tumor aberrations. Limitation of Use: ALIMTA is not indicated for the treatment of patients with squamous cell non-small cell lung cancer.

Research 52

Research Clinical Trials Clinical Trials Trials 52